Telehealth Ketamine State Regulations Overview

The legal landscape governing telehealth ketamine is layered, rapidly evolving, and varies significantly depending on where you live and where your provider is located. Understanding this framework is essential for patients trying to access care and for clinicians trying to practice compliantly. This overview covers the key federal and state regulatory dimensions.

The Federal Framework

Ketamine as a Controlled Substance

Ketamine is classified as a Schedule III controlled substance under the Controlled Substances Act. Schedule III drugs have accepted medical uses but carry potential for abuse. This classification means that prescribing, dispensing, and possessing ketamine is subject to DEA regulations.

The Ryan Haight Act

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 was enacted to prevent pill mills from dispensing controlled substances via the internet without proper evaluation. Its key provision: a practitioner generally cannot prescribe a controlled substance via the internet (including via telehealth) without first conducting an in-person medical evaluation of the patient.

This requirement created a significant barrier to telehealth ketamine prescribing, since it meant every new patient required an in-person visit before a prescription could be issued remotely. Our DEA compliance guide covers the full history and current status of these requirements.

COVID-19 Flexibilities

During the COVID-19 public health emergency declared in March 2020, the DEA issued blanket exemptions allowing practitioners to prescribe Schedule II-V controlled substances via telehealth without a prior in-person visit. These exemptions enabled the telehealth ketamine industry to emerge and grow substantially.

As of 2024, the DEA has extended these exemptions while it works to develop a permanent Special Registration framework for telemedicine controlled substance prescribing. The extensions have been challenged, debated, and renewed multiple times. Patients and providers should monitor DEA announcements, as the status of these exemptions directly affects telehealth access.

DEA Special Registration

The SUPPORT for Patients and Communities Act of 2018 directed the DEA to create a special registration that would allow practitioners to prescribe controlled substances via telemedicine without a prior in-person visit, subject to specific conditions. As of early 2024, the DEA has proposed—but not yet finalized—rules for this special registration.

The proposed framework would allow:

• A "telemedicine prescribing registration" for providers meeting eligibility requirements
• A registry of patients receiving controlled substances via telemedicine
• Certain safeguards including identity verification and coordination with PDMPs

Until this framework is finalized and implemented, the legal basis for telehealth ketamine prescribing rests on the extended COVID exemptions.

State Licensing Requirements

Provider Licensing

Regardless of federal controlled substance rules, a healthcare provider must hold a valid license in the state where the patient is located to practice medicine in that state. This is distinct from where the provider physically sits. If you are in California and your provider is in New York, the provider must hold a California medical license to legally evaluate and treat you.

Many telehealth platforms address this by employing providers licensed in multiple states or by restricting access to states where their providers hold licenses.

The Interstate Medical Licensure Compact (IMLC)

The IMLC is an agreement among participating states that streamlines the process for physicians to obtain licenses in multiple states. As of 2024, over 40 states participate. Providers licensed through the IMLC can more easily expand their telehealth practice across state lines, increasing access in those states.

Nurse practitioners and physician assistants have their own compact (see our article on nurse practitioner prescribing authority for details)—the Nurse Licensure Compact (NLC) and the Physician Assistant Licensure Compact (PALC)—which similarly facilitate multi-state practice.

State Telehealth Practice Standards

States vary in how they regulate telehealth practice itself:

Prescribing Standards

Some states have enacted their own requirements for telehealth prescribing of controlled substances, independent of federal law. These may include:

• Mandatory in-person evaluation before prescribing certain drug classes (some states retain this requirement even if federal exemptions apply)
• Limitations on how long a telehealth relationship can substitute for an in-person relationship
• State-specific PDMP participation requirements

Consent and Documentation

Most states require informed consent for telehealth services, and some require that consent explicitly acknowledge the telehealth modality. Documentation standards vary—some states require the provider's location, the patient's location, and the technology used to be noted in the medical record.

Pharmacy and Compounding Rules

The pharmacy that compounds and dispenses ketamine must be licensed to dispense in the patient's state. Compounding pharmacy rules vary by state, and some states have additional restrictions on compounded controlled substances. This pharmacy layer adds another regulatory variable to the access equation.

States With Notable Restrictions

While this guide does not provide state-by-state legal advice, certain patterns emerge:

States with stricter telehealth prescribing standards may require that telehealth controlled substance prescribing comply with standards equivalent to in-person care, limiting the utility of federal exemptions.

States that have not joined the IMLC or similar compacts may have fewer providers licensed to practice there, reducing the number of telehealth platforms available to residents.

States with additional compounding restrictions may limit access to compounded sublingual ketamine even when prescribing is legally permissible.

State Boards of Medicine and Nursing

State medical and nursing boards retain authority over licensure standards and professional conduct, independent of DEA rules. A provider can comply with the DEA's telehealth prescribing framework and still violate their state board's practice standards. Boards have issued guidance on telehealth, and in some cases have disciplined providers for prescribing controlled substances via telemedicine in ways deemed below the standard of care.

What This Means for Patients

As a patient, the key practical implications are:

1. Your access depends on your location. Not all telehealth ketamine platforms operate in all states, and some states have more robust access than others.
2. Your provider must be licensed in your state. If a platform cannot confirm its providers are licensed in your state, they cannot legally serve you.
3. The regulatory environment is in flux. What is permissible today may change as DEA finalizes permanent rules. Programs that launched under COVID exemptions may face operational changes when the permanent framework takes effect.
4. Compounding pharmacy logistics matter. Where the pharmacy is located, and whether it is licensed in your state, affects whether your medication can legally be shipped to you.
5. State-specific rules may add requirements. Even if a federal exemption applies, your state may have additional requirements you or your provider must meet.

Staying informed about changes in the regulatory environment—or working with a platform that does so on your behalf—is part of navigating telehealth ketamine access effectively. For state-specific information, browse our state guides.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• HHS: Telehealth — U.S. Department of Health and Human Services guide to telehealth services, regulations, and patient resources
• SAMHSA: National Helpline — Substance Abuse and Mental Health Services Administration free treatment referral and information service